Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR,Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB,Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, SetnikB, Sokolowska M, Stauffer JW, Walsh SL. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 2012 Dec;153(12):2315-24. doi: 10.1016/j.pain. 2012.07.035. Epub 2012 Sep 19. PubMed PMID: 22998781; PubMed Central PMCID: PMC3494795.
Schoedel KA, Pope LE, Sellers EM. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clin Drug Investig. 2012 Mar 1;32(3):157-69. doi: 10.2165/11599870-000000000-00000.PubMed PMID: 22283559.
Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L.Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Clin Ther. 2012 May;34(5):1170-81. doi:10.1016/j.clinthera.2012.02.010. Epub 2012 Apr 17. PubMed PMID: 22512898.
Pope LE, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clin Drug Investig. 2012 Aug 1;32(8):e1-15. doi: 10.2165/11633850-000000000-00000. PubMedPMID: 22712629.
Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. J Clin Psychopharmacol. 2012 Aug;32(4):492-502. doi:10.1097/JCP.0b013e31825d380d. PubMed PMID: 22722508.
Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, et al. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. Journal of clinical psychopharmacology. 2012;32(4):492-502. Epub 2012/06/23.
